Aptevo Therapeutics Inc Stock Price, News & Analysis

Aptevo Therapeutics (Nasdaq:APVO) reported Q2 2025 financial results and significant clinical progress. The company's lead candidate mipletamig achieved an 85% remission rate in frontline AML patients across two trials. Aptevo expanded its CD3 bispecific portfolio by introducing APVO455, a Nectin-4 x CD3 bispecific targeting multiple solid tumors.

The company raised $15.9 million in Q2 2025, extending its cash runway into late Q4 2025, with an additional $25 million equity line of credit secured. Q2 financial results showed cash position of $9.4 million and a net loss of $6.2 million ($8.40 per share), compared to a $5.9 million loss in Q2 2024.

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotech company, has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules, raising $8 million in gross proceeds. The offering included 2,465,000 shares of common stock or pre-funded warrants, along with warrants to purchase up to 12,325,000 shares at $3.25 per share. Each common stock share comes with five Common Warrants exercisable upon stockholder approval, with a five-year expiration term. Roth Capital Partners served as the placement agent. The company plans to use the proceeds for clinical development of its product candidates, working capital, and general corporate purposes.

Aptevo Therapeutics (NASDAQ: APVO) has expanded its CD3-directed portfolio with APVO455, a new preclinical candidate targeting Nectin-4+ cancers. The company now has three CD3-engaging molecules sharing the CRIS-7 derived binding domain: mipletamig (CD123 x CD3) in Phase 1b/2 for AML with 85% remission rate, APVO442 (PSMA x CD3) for prostate cancer in preclinical development, and APVO455 (Nectin-4 x CD3) for multiple solid tumors. The CRIS-7 platform has demonstrated strong clinical validation through mipletamig's performance, where over 100 patients across three trials showed no cytokine release syndrome in initial cohorts. This expansion represents Aptevo's strategic move from hematologic to solid tumors, with a focus on developing therapeutics that combine tumor-specific immune activation with limited systemic toxicity.

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotech company, has announced a registered direct offering priced at-the-market under Nasdaq rules to raise $8 million. The offering includes 2,465,000 shares of common stock or pre-funded warrants, along with warrants to purchase up to 12,325,000 shares at $3.25 per share. Each common stock share comes with five Common Warrants exercisable upon stockholder approval, with a five-year expiration term. The offering, expected to close around June 20, 2025, is being facilitated by Roth Capital Partners. Proceeds will support clinical development of product candidates, working capital, and general corporate purposes. The offering is made through a Form S-1 registration statement declared effective by the SEC.

Aptevo Therapeutics (NASDAQ:APVO) reported promising clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a CD123 x CD3 bispecific antibody, combined with venetoclax and azacitidine for frontline AML patients unfit for intensive chemotherapy. The triplet therapy achieved an impressive 85% remission rate across two trials, significantly outperforming competitor studies. Notable safety outcomes include no cytokine release syndrome (CRS) in cohorts 1 and 2. Three patients with poor prognosis achieved complete remission, with one successfully proceeding to transplant. The trial's Cohort 3 is nearing full enrollment at the highest dose level. Mipletamig's unique CRIS-7 binding domain engineering strategy demonstrates potential in mitigating cytokine-related toxicity while maintaining anti-cancer activity.

Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotech company specializing in immuno-oncology therapeutics through its ADAPTIR® and ADAPTIR-FLEX® platforms, announced its participation in the BIO International Convention from June 16-19, 2025, in Boston, MA. The event, recognized as the largest biotech industry conference of the year, is expected to draw over 18,000 global attendees. Aptevo will be represented by Dr. Michelle N. Nelson, Director of Immunobiology, and SoYoung Kwon, SVP, General Counsel and Head of Business Development.

Aptevo Therapeutics (NASDAQ:APVO) has announced a 1-for-20 reverse stock split effective May 23, 2025, at 5:01 p.m. Eastern Time. Trading on the adjusted basis will begin on May 27, 2025. The reverse split will reduce outstanding shares from approximately 13.5 million to 0.7 million.

The measure, approved by stockholders on May 14, 2025, and finalized by the Board on May 21, 2025, is part of the company's strategy to maintain Nasdaq Capital Market listing compliance. The split will affect all outstanding shares, options, restricted stock units, and warrants. No fractional shares will be issued, with cash payments provided instead. The trading symbol "APVO" and the stock's par value of $0.001 will remain unchanged.

Aptevo Therapeutics (NASDAQ: APVO) reported significant progress in its RAINIER Phase 1b/2 trial for mipletamig, a treatment for frontline acute myeloid leukemia (AML). The drug, combined with standard care (venetoclax and azacitidine), achieved a 90% remission rate (9 out of 10 patients) across two trials. Key highlights include:

- 5 out of 6 patients in RAINIER trial achieved remission within 30 days - No cytokine release syndrome (CRS) observed in current trial - One patient achieved complete remission with MRD-negative status - Cohort 2 enrollment completed, Cohort 3 now enrolling

The drug has been tested in nearly 100 patients across three clinical studies, showing promising results in both combination and monotherapy settings. In monotherapy trials, 36% of evaluable patients who failed prior treatments showed significant leukemic blast reduction. The company plans multiple data readouts in 2025.

Aptevo Therapeutics (NASDAQ: APVO) provided an update on APVO711, their preclinical-stage bispecific therapeutic candidate. APVO711 is designed with a dual mechanism that combines PD-L1 checkpoint inhibition with CD40 immune activation, developed using their proprietary ADAPTIR® platform technology.

The company's lead candidate mipletamig continues to show strong efficacy and safety results in AML trials. APVO711 demonstrates promising preclinical results with potential applications across various solid tumors, particularly those resistant to conventional checkpoint therapies. The therapeutic aims to achieve deeper and more sustained responses through its innovative dual-mechanism approach.